AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16790650 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine 0.125% and sufentanil 0.75 microg/mL without epinephrine
Number of subjects: 70
Study 15518616 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial approach
Number of subjects: 377
Study 15518616 — intervention group
Group type: COMPARATOR
Intervention: Femoral approach
Number of subjects: 377
Study 11103159 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalosporin antibiotic
Number of subjects: 76
Study 11103159 — intervention group
Group type: COMPARATOR
Intervention: Bag extraction of the dissected gallbladder
Number of subjects: 76
Study 9396959 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline or paroxetine (SSRIs) for 6 weeks
Number of subjects: 25
Study 8403959 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (0.06 to 0.2 microgram/kg/min)
Number of subjects: 21
Study 8403959 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (0.02 to 0.2 microgram/kg/min)
Number of subjects: 21
Study 8403959 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (3 to 12 micrograms/kg/min)
Number of subjects: 21
Study 3945711 — intervention group
Group type: EXPERIMENTAL
Intervention: Napping
Number of subjects: 94
Study 3945711 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting
Number of subjects: 94
Study 3945711 — intervention group
Group type: COMPARATOR
Intervention: Control (watching a neutral videotape)
Number of subjects: 94
Study 29760054 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo treatment
Number of subjects: 0
Study 29760054 — intervention group
Group type: COMPARATOR
Intervention: Intranasal administration of oxytocin
Number of subjects: 0
Study 27256094 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention including booklets, education sessions, resistance bands, and local walking groups
Number of subjects: 600
Study 27256094 — intervention group
Group type: COMPARATOR
Intervention: Standard and 1-time advice (control group)
Number of subjects: 600
Study 25515179 — intervention group
Group type: EXPERIMENTAL
Intervention: SPOTLIGHT‐Virtual Audit Tool (S‐VAT)
Number of subjects: 128
Study 22199246 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 15
Study 22199246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 20451523 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesogaberan (65 mg)
Number of subjects: 27
Study 20451523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 18564348 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mcg alprostadil cream
Number of subjects: 400
Study 18564348 — intervention group
Group type: EXPERIMENTAL
Intervention: 700 mcg alprostadil cream
Number of subjects: 400
Study 18564348 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mcg alprostadil cream
Number of subjects: 400
Study 18564348 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 400
Study 16167910 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac hydroxyethyl pyrrolidine (100 mg)
Number of subjects: 261
Study 16167910 — intervention group
Group type: COMPARATOR
Intervention: Ketoprofen (100 mg)
Number of subjects: 261
Study 12859696 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan (50 mg o.d.)
Number of subjects: 24
Study 12859696 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 11130221 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric enteral nutrition (EN)
Number of subjects: 0
Study 11130221 — intervention group
Group type: EXPERIMENTAL
Intervention: Prokinetic agents (cisapride, erythromycin, metoclopramide)
Number of subjects: 0
Study 11130221 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 0
Study 11130221 — intervention group
Group type: EXPERIMENTAL
Intervention: Transpyloric migration of the feeding tube
Number of subjects: 0
Study 9352040 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteosynthesis
Number of subjects: 20
Study 9352040 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Hip Arthroplasty (THA)
Number of subjects: 20
Study 9352040 — intervention group
Group type: COMPARATOR
Intervention: Reference group (THA due to arthrosis)
Number of subjects: 20
Study 8157039 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg (AT)
Number of subjects: 12
Study 8157039 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide 5 mg (BFZ)
Number of subjects: 12
Study 8157039 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Atenolol 100 mg and Bendrofluazide 5 mg (AT/BFZ)
Number of subjects: 12
Study 8157039 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 5 mg (Dz)
Number of subjects: 12
Study 8157039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3538476 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled piriprost 1 mg
Number of subjects: 12
Study 3538476 — intervention group
Group type: COMPARATOR
Intervention: Vehicle placebo
Number of subjects: 12
Study 31082749 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginseng extract
Number of subjects: 74
Study 31082749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 28479294 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype novel tobacco vapor (PNTV) product
Number of subjects: 0
Study 28479294 — intervention group
Group type: COMPARATOR
Intervention: Conventional cigarette (CC1)
Number of subjects: 0
Study 26179891 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling and n-3 PUFA supplementation (2.4 g/d) for 36 months
Number of subjects: 563
Study 23726602 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizoribine (MZR)
Number of subjects: 110
Study 23726602 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 110
Study 23726602 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizoribine (MZR) after dose change
Number of subjects: 110
Study 23726602 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) after dose change
Number of subjects: 110
Study 21568751 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Testing Group (STG)
Number of subjects: 483
Study 21568751 — intervention group
Group type: COMPARATOR
Intervention: Active Control Group (ACG)
Number of subjects: 483
Study 18582179 — intervention group
Group type: EXPERIMENTAL
Intervention: d-MPH-ER 20 mg/day
Number of subjects: 84
Study 18582179 — intervention group
Group type: EXPERIMENTAL
Intervention: d-MPH-ER 30 mg/day
Number of subjects: 84
Study 18582179 — intervention group
Group type: EXPERIMENTAL
Intervention: d,l-MPH-ER 36 mg/day
Number of subjects: 84
Study 18582179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 16861611 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-2 low dose (0.1 microg/kg per hour)
Number of subjects: 19
Study 16861611 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-2 high dose (1 mug/kg per hour)
Number of subjects: 19
Study 16861611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 14561022 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid suppressive therapy (AST)
Number of subjects: 301
Study 14561022 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgical and general internal medicine ward)
Number of subjects: 301
Study 10746106 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-rich cola
Number of subjects: 11
Study 10746106 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-free cola
Number of subjects: 11
Study 10746106 — intervention group
Group type: COMPARATOR
Intervention: Mineral water
Number of subjects: 11
Study 8679353 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 10 micrograms/kg body weight with lignocaine
Number of subjects: 60
Study 8679353 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 10 ml with lignocaine
Number of subjects: 60
Study 1932606 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous carbimide doses of 0.1, 0.3, 0.6, and 1 mg kg‐1
Number of subjects: 0
Study 1932606 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral carbimide doses of 1 and 1.5 mg kg‐1
Number of subjects: 0
Study 1932606 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral carbimide doses of 0.3 and 1 mg kg‐1
Number of subjects: 0
Study 6410735 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonionic contrast medium, iohexol
Number of subjects: 60
Study 6410735 — intervention group
Group type: COMPARATOR
Intervention: Ionic contrast medium, sodium metrizoate
Number of subjects: 60
Study 6410735 — intervention group
Group type: EXPERIMENTAL
Intervention: Both contrast media
Number of subjects: 60
Study 30992235 — intervention group
Group type: EXPERIMENTAL
Intervention: CVT‐301 84 mg
Number of subjects: 36
Study 30992235 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbidopa/levodopa + CVT‐301
Number of subjects: 36
Study 30992235 — intervention group
Group type: COMPARATOR
Intervention: Carbidopa/levodopa + placebo
Number of subjects: 36
Study 28824029 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 221
Study 28824029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 26361207 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 IU FSH
Number of subjects: 356
Study 26361207 — intervention group
Group type: COMPARATOR
Intervention: 600 IU FSH
Number of subjects: 356
Study 24656524 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine plus sertraline
Number of subjects: 259
Study 24656524 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine plus placebo
Number of subjects: 259
Study 23031071 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week physical activity and nutrition intervention
Number of subjects: 0
Study 23031071 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week maintenance program
Number of subjects: 0
Study 19207292 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg tid
Number of subjects: 2550
Study 19207292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2550
Study 18075285 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene supplementation (10 mg/day)
Number of subjects: 35
Study 18075285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 15379366 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod cream 5%
Number of subjects: 23
Study 15379366 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 23
Study 12142559 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive immunotherapy with anti‐CD3‐expanded tumor vaccine draining lymph node lymphocytes (TVDLN) combined with systemic IL‐2 after vaccination with gene-modified autologous tumor cells.
Number of subjects: 20
Study 12142559 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene-modified tumor cells expressing HLA-B7 and β2-microglobulin.
Number of subjects: 20
Study 12142559 — intervention group
Group type: EXPERIMENTAL
Intervention: TVDLN lymphocytes activated and expanded ex vivo with anti‐CD3 and IL‐2.
Number of subjects: 20
Study 12142559 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymph nodes harvested from patients.
Number of subjects: 20
Study 12142559 — intervention group
Group type: EXPERIMENTAL
Intervention: MHC class I restricted, tumor‐specific cytokine secretion observed in lymphocytes.
Number of subjects: 20
Study 9582132 — intervention group
Group type: EXPERIMENTAL
Intervention: Four layer compression bandaging in a leg ulcer clinic
Number of subjects: 233
Study 9582132 — intervention group
Group type: COMPARATOR
Intervention: Usual care at home by the district nursing service
Number of subjects: 233
Study 8610712 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (500 micrograms, nebulized, three times daily)
Number of subjects: 223
Study 8610712 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (2.5 mg, nebulized, three times daily)
Number of subjects: 223
Study 1707333 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg b.i.d. of ketotifen
Number of subjects: 10
Study 1707333 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg b.i.d. of ketotifen
Number of subjects: 10
Study 7192125 — intervention group
Group type: EXPERIMENTAL
Intervention: fenbufen (1000 mg/d)
Number of subjects: 25
Study 7192125 — intervention group
Group type: COMPARATOR
Intervention: acetylsalicylic acid (ASA) (3600 mg/d)
Number of subjects: 25
Study 30427749 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-valent pneumococcal conjugate vaccine (PCV15)
Number of subjects: 250
Study 30427749 — intervention group
Group type: COMPARATOR
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 250
Study 27863323 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-informed group (n=379)
Number of subjects: 1143
Study 27863323 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-informed group (n=385)
Number of subjects: 1143
Study 27863323 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=379)
Number of subjects: 1143
Study 26048851 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with defibrillator (CRT-D)
Number of subjects: 1278
Study 23839541 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day)
Number of subjects: 6595
Study 24567990 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality salience induction (experimental induction)
Number of subjects: 1056
Study 24567990 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality salience induction (experimental induction) with crime drama showing justice being carried out
Number of subjects: 1056
Study 24567990 — intervention group
Group type: COMPARATOR
Intervention: Induction to think about pain (control group)
Number of subjects: 1056
Study 20308765 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc and multivitamin supplement (2mg/kg/day for 6 weeks)
Number of subjects: 100
Study 20308765 — intervention group
Group type: COMPARATOR
Intervention: Only multivitamin supplement
Number of subjects: 100
Study 17653789 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-enhancing enteral formula (IEEF), n = 16
Number of subjects: 30
Study 17653789 — intervention group
Group type: COMPARATOR
Intervention: Regular polymeric enteral formula (Control), n = 14
Number of subjects: 30
Study 15831778 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-mg HHER q24h
Number of subjects: 0
Study 15831778 — intervention group
Group type: COMPARATOR
Intervention: 3-mg HHIR q6h
Number of subjects: 0
Study 15831778 — intervention group
Group type: EXPERIMENTAL
Intervention: HHER
Number of subjects: 0
Study 11981006 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilized peripheral-blood stem-cell transplantation (PBSCT)
Number of subjects: 93
Study 11981006 — intervention group
Group type: COMPARATOR
Intervention: Autologous bone marrow transplantation (ABMT)
Number of subjects: 93
Study 10386509 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean Red Meat (LRM)
Number of subjects: 191
Study 10386509 — intervention group
Group type: COMPARATOR
Intervention: Lean White Meat (LWM)
Number of subjects: 191
Study 8919830 — intervention group
Group type: EXPERIMENTAL
Intervention: Low flow circuit (fresh gas flow 700 ml/min)
Number of subjects: 50
Study 8919830 — intervention group
Group type: COMPARATOR
Intervention: Open system ventilation
Number of subjects: 50
Study 2104806 — intervention group
Group type: EXPERIMENTAL
Intervention: Human menopausal gonadotropin (hMG)
Number of subjects: 37
Study 2104806 — intervention group
Group type: COMPARATOR
Intervention: Follicle-stimulating hormone (FSH)
Number of subjects: 37
Study 332465 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadiazine (SD) 1,000 MG/Trimethoprim (TM) 320 mg
Number of subjects: 198
Study 332465 — intervention group
Group type: COMPARATOR
Intervention: Sulfamethoxazole (SM) 1,600 mg/Trimethoprim 320 mg
Number of subjects: 198
Study 31466505 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern/Audio‐Visual
Number of subjects: 40
Study 31466505 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern/Visual
Number of subjects: 40
Study 31466505 — intervention group
Group type: COMPARATOR
Intervention: Pattern-Goal/Visual
Number of subjects: 40
Study 31466505 — intervention group
Group type: COMPARATOR
Intervention: Pattern-Goal/Audio-Visual
Number of subjects: 40
Study 31466505 — intervention group
Group type: COMPARATOR
Intervention: Visual-only
Number of subjects: 40
Study 29135802 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 120
Study 29135802 — intervention group
Group type: COMPARATOR
Intervention: Panretinal photocoagulation
Number of subjects: 120
Study 29258499 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS education intervention (daily messages and weekly reminders)
Number of subjects: 73
Study 29258499 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional paper-based educational material)
Number of subjects: 73
Study 29258499 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS education intervention
Number of subjects: 73
Study 29258499 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study 25951417 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic esophageal myotomy (LEM)
Number of subjects: 50
Study 25951417 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic pneumatic dilatation (EPD)
Number of subjects: 50
Study 23588319 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg
Number of subjects: 24
Study 23588319 — intervention group
Group type: COMPARATOR
Intervention: Mirtazapine 30 mg
Number of subjects: 24
Study 23588319 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving performance (SD of lateral position)
Number of subjects: 24
Study 21775558 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss intervention (n = 291; mean weight loss: 4.4 kg)
Number of subjects: 585
Study 21775558 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 294; mean weight loss: 0.8 kg)
Number of subjects: 585
Study 19567093 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose (200 mg once a week for 4 weeks, then 100 mg once a week for 8 weeks for HD subgroup; 200 mg once a week for 4 weeks, then 200 mg once every other week for 8 weeks for PD subgroup)
Number of subjects: 194
Study 19567093 — intervention group
Group type: COMPARATOR
Intervention: Oral medication (ferrous succinate 200 mg tid for 12 weeks)
Number of subjects: 194
Study 19567093 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose
Number of subjects: 194
Study 19567093 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose (PD subgroup)
Number of subjects: 194
Study 19567093 — intervention group
Group type: COMPARATOR
Intervention: Oral medication
Number of subjects: 194
Study 19567093 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO + intravenous iron sucrose
Number of subjects: 194
Study 16734581 — intervention group
Group type: EXPERIMENTAL
Intervention: Two two‐piece implants placed in a non‐submerged procedure
Number of subjects: 60
Study 16734581 — intervention group
Group type: EXPERIMENTAL
Intervention: Two two‐piece implants placed in the traditional submerged procedure
Number of subjects: 60
Study 16734581 — intervention group
Group type: EXPERIMENTAL
Intervention: Two one‐piece dental implants placed in the traditional non‐submerged procedure
Number of subjects: 60
Study 16734581 — intervention group
Group type: EXPERIMENTAL
Intervention: Microgap at the crestal level in two‐piece implants
Number of subjects: 60
Study 16734581 — intervention group
Group type: COMPARATOR
Intervention: All groups (non-submerged, submerged, one-piece)
Number of subjects: 60
Study 15229957 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg twice weekly by subcutaneous injection
Number of subjects: 205
Study 15229957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 11718737 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-Fix
Number of subjects: 896
Study 11718737 — intervention group
Group type: COMPARATOR
Intervention: DCP
Number of subjects: 896
Study 9150822 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg paroxetine (n = 271)
Number of subjects: 544
Study 9150822 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg maprotiline (n = 273)
Number of subjects: 544
Study 9150822 — intervention group
Group type: COMPARATOR
Intervention: 40 mg paroxetine (n = 50)
Number of subjects: 544
Study 9150822 — intervention group
Group type: COMPARATOR
Intervention: 150 mg maprotiline (n = 40)
Number of subjects: 544
Study 8881802 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg twice daily for four to eight weeks (H pylori negative ulcers)
Number of subjects: 278
Study 8881802 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg twice daily plus amoxycillin 1 g twice daily for the first two weeks (H pylori positive ulcers)
Number of subjects: 278
Study 8881802 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole alone for four to eight weeks while continuing NSAID therapy (H pylori positive ulcers)
Number of subjects: 278
Study 8881802 — intervention group
Group type: EXPERIMENTAL
Intervention: H pylori eradication
Number of subjects: 278
Study 8881802 — intervention group
Group type: COMPARATOR
Intervention: Cumulative recurrence rates at six months
Number of subjects: 278
Study 2805366 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% aqueous lignocaine infiltrated into the nasal vestibule
Number of subjects: 26
Study 2805366 — intervention group
Group type: COMPARATOR
Intervention: Topical anaesthesia of the nasal mucous membrane
Number of subjects: 26
Study 1099859 — intervention group
Group type: EXPERIMENTAL
Intervention: oestradiolvalerate/norgestrel sequential therapy
Number of subjects: 33
Study 1099859 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 33
Study 31169952 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous ovulation monitored by urinary luteinising hormone (LH)
Number of subjects: 392
Study 31169952 — intervention group
Group type: COMPARATOR
Intervention: Induced ovulation by administration of human chorionic gonadotrophin (hCG)
Number of subjects: 392
Study 26970975 — intervention group
Group type: EXPERIMENTAL
Intervention: HSS-Group (closed-loop system for propofol administration)
Number of subjects: 150
Study 26970975 — intervention group
Group type: COMPARATOR
Intervention: Control Group (manual administration of propofol)
Number of subjects: 150
Study 26088663 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Start Denver Model (ESDM)
Number of subjects: 39